基因總覽
VCP(valosin containing protein)是蛋白質編碼基因,其產物屬於 AAA ATPase 家族。蛋白質由 806 個胺基酸組成,並可組成六聚體;其環狀組裝與多種細胞內複合體的形成相關。C 端含有與 UBXN6 互作的區域及 PIM motif,部分區域則被註記為無序區。VCP 在細胞中扮演多面向角色,涵蓋膜與蛋白質的處理、細胞分裂及 DNA 損傷相關過程。
基因異名與舊稱
異名取自 HGNC,可能包含歷史名稱;蛋白質名稱以 UniProt 註解為準。
染色體位置與基因結構
查看實際轉錄本與 exon 註解
| Transcript | Genomic coordinates | Exons |
|---|---|---|
| ENST00000358901 ★ | 35,056,064–35,072,625 | 17 |
| ENST00000679902 | 35,053,928–35,072,671 | 16 |
| ENST00000678650 | 35,055,357–35,072,561 | 17 |
| ENST00000677257 | 35,055,357–35,072,671 | 17 |
| ENST00000448530 | 35,055,357–35,072,668 | 17 |
| ENST00000681335 | 35,055,357–35,072,671 | 16 |
| ENST00000417448 | 35,055,357–35,072,205 | 17 |
| ENST00000679862 | 35,055,357–35,072,611 | 17 |
| ENST00000854254 | 35,055,357–35,072,671 | 16 |
| ENST00000854255 | 35,055,357–35,072,671 | 17 |
| ENST00000854256 | 35,055,357–35,072,671 | 16 |
| ENST00000940607 | 35,055,357–35,072,671 | 17 |
顯示 12/27 個蛋白質編碼轉錄本;canonical 優先。
帶型與著絲點依 Ensembl 座標繪製;核染色體長度以 GRCh38 第 1 號染色體為共同尺度。黃色標記表示本基因位置,細小區間加粗以利辨識;實際基因長度與 exon 見下方資料。
分子功能與生物學過程
VCP 是 ATP 水解酶,將 ATP 與水轉換為 ADP、磷酸及氫離子。其重要作用之一,是協助處理錯誤摺疊或受損蛋白質:VCP 與 UFD1、NPLOC4 組成的複合體可辨識泛素化蛋白,將內質網中的錯誤摺疊蛋白移至細胞質,再由蛋白酶體降解。VCP 也參與內質網壓力誘發的預先品質管制,使新合成蛋白質進入內質網的轉位受到選擇性抑制,並改送至細胞質降解;此外,它參與受損粒線體外膜蛋白的逆向轉位與降解,以及含泛素自噬體的成熟和泛素化蛋白的自噬清除。
在膜與細胞器調節方面,VCP 參與內質網向高基氏體的膜運輸、過渡性內質網形成,以及有絲分裂期間高基氏體堆疊的分裂與分裂後重組。它也參與有絲分裂末期的紡錘體解聚及封閉核膜形成。VCP 所在的複合體可參與 HMGCR 的固醇介導泛素化與內質網相關降解(ERAD)末步;在皮質神經元中,VCP 也透過 STUB1-VCP-UBXN2A 複合體介導 CHRNA3 的 ERAD。對於壓力顆粒,VCP 可協助抽離 G3BP1;它也可能參與膜蛋白送往溶小體降解的泛素依賴性分選,尤其可能涉及 caveolins。
VCP 亦參與 DNA 損傷處理。它會以 RNF8 與 RNF168 依賴的方式被募集至 DNA 雙股斷裂處,並促進 TP53BP1 到達損傷位點。在 SPRTN 招募下,VCP 會到達停滯的複製叉,可能透過抽離 DNA polymerase eta(POLH),避免跨損傷合成過度並限制損傷誘發突變;它也與 SPRTN metalloprotease 共同參與 DNA 合成期間共價 DNA-蛋白質交聯的修復。面對複製壓力時,VCP 參與卸載泛素化 CMG helicase 複合體;它也能辨識泛素化 PARP1,促進被困於染色質的 PARP1 移除。
在免疫與訊號調節方面,當 RIGI 的 CARD 結構域帶有 Lys-63 連結的泛素時,VCP 與 RIGI 互作並招募 RNF125,促進 RIGI 泛素化及降解,因此負向調節 type I interferon 生成。VCP 也透過控制 IGF1R 的穩態表現,間接調節 insulin-like growth factor receptor 訊號;並可調節 RNF19A 的 E3 ubiquitin-protein ligase 活性。
Promoter 與基因調控
>VCP ENST00000358901 GRCh38 chr9:35072525-35073625 strand=-1 5′→3′ 相對 TSS:-1000 到 +100 bp;1101 bp 依轉錄本 TSS 擷取的基因組序列;TSS = 0,兩端包含,未驗證為 promoter ATGAGTGGAGTTGGGTCTGAAGGGTGGTCTAGATAGGCCTCTCAGGACAAGGGCAGGTACCTGTTACTTA GAGACAGGCAGGTTTCTCTCAGAGTAACTCTTCACTCCCTTCCTAATTCCAAATTCTAGAAATTCGACTC GTCTTAGTCAAATGTGTCTGTGTGGGTACAGGGTGAAAGGTGAATTGAGTCAGCATATCACCAACAGCTG CCTGTTGACTACTAACAGGGACCCCTGTTATTTGGGGCCCAAGGATTTTCAAGTCCCAGCATATGCAGTT TTCTTGCTAATTTGGGTTCTACTGAATTGGCTGTGTGTTCTGTGGTTGCCCTTTGACTTCTCTGGATTTG AGTGCCTTATTATAAGGTATTAATATTAATGACGGGAGGAAGAAAGGCACAAGCGCTGAGAAACTGCAAA GGCTGTGGGATTGGGGTTACCAGAGGGTGCAGTGACAATGGGGTAGGAGTGGGGTGCTAGTCAGAAAGTT CAGAGTAGGGGTGGTTGGAGGCAGCGTTGAGAAGGAGCAAGAAGTGTCAGGGTGGTGATGGCGTCTTAGA AGATCTCCAGGTTTTGGGAGAAGATGGGTGTATGGGTTACCACAATAGGACTAGACTAATACAAGGGTTC AGTCTATTGTGCCACGTTCTTCCAGGAGGATAAACTCCGGAGCCAATGAACTGGAGCCAAGTGGGAGAGT CCGCCTCTAAGGGATTAAAGGGTCTCCTTTCACTAATCGATCTCGCCCTATTCCTTTCGTTGATTGGCTG AGAATTCCAATCCGTCGAGGAAGCGTAGCGTTGCGGCCAATTGACGTGGCGTTACTAGGCGTGTCGCATC ACTGAGGCGGGAGCCAGGCCGCAAGCGAATTTCCTGATTGGCTGTGATCTGCGGGTTGCTGGGGAGAGGC GCGGAGAGGCGGGCGAGAGTCCGCAGGGCAGGCGCTGATTGGCTGAGGTGGGAGCAGCTTCCCTTCCGAT GATTCGGCTCTTCTCGGCTCAGTCTCAGCGAAGCGTCTGCGACCGTCGTTTGAGTCGTCGCTGCCGCTGC CGCTGCCACTGCCACTGCCACCTCGCGGATCAGGAGCCAGCGTTGTTCGCC
EPDnew 實驗支持 promoter/TSS · 1 筆
| EPDnew ID | TSS(1-based) | 股向 | 來源顯示區間 |
|---|---|---|---|
| VCP_1 ↗ | 9:35,072,625 | 負股 | 35,072,615–35,072,674 |
EPDnew human v006 · UCSC hg38,GRCh38/hg38,透過 UCSC 取得。TSS 具有 CAGE/RAMPAGE 等實驗資料支持;任意擷取的上下游區間仍需另行判讀調控功能,不能視為整段皆經功能驗證。
EPD 封存狀態 ↗ · UCSC 資料說明 ↗ · EPD team, SIB Swiss Institute of Bioinformatics; UCSC Genome Browser · CC BY 4.0
查看已取得的調控/motif 註解
ENSR9_B8XWS · enhancer · 35070060–35070614 · regulatory
ENSR9_C5GZ2 · enhancer · 35070818–35072194 · regulatory
ENSR9_B8XX6 · promoter · 35072195–35073158 · regulatory
ENSR9_5B8PQB · CTCF_binding_site · 35072196–35072217 · regulatory
ENSR9_5B8PRX · CTCF_binding_site · 35072544–35072565 · regulatory
· motif · 35070232–35070246 · motif
· motif · 35070232–35070246 · motif
· motif · 35071036–35071051 · motif
· motif · 35071036–35071051 · motif
· motif · 35071754–35071763 · motif
· motif · 35071880–35071890 · motif
· motif · 35071927–35071940 · motif
· motif · 35071927–35071940 · motif
· motif · 35072198–35072214 · motif
· motif · 35072373–35072390 · motif
· motif · 35072382–35072397 · motif
· motif · 35072474–35072489 · motif
· motif · 35072546–35072562 · motif
· motif · 35072729–35072744 · motif
· motif · 35072747–35072758 · motif
· motif · 35073286–35073299 · motif
· motif · 35073298–35073313 · motif
· motif · 35073298–35073315 · motif
· motif · 35073443–35073456 · motif
蛋白質結構域與序列
參考蛋白質長度:806 aa
VCP 蛋白長 806 個胺基酸,屬於 AAA ATPase 家族。第 708–727 位及 768–806 位胺基酸區段被註記為無序區;第 797–806 位區段參與與 UBXN6 的互作,末端第 802–806 位含有 PIM motif。
蛋白質三維結構
細胞內定位
VCP 可位於細胞質、細胞溶質、內質網、細胞核及壓力顆粒。 定位會隨情境改變:它可經 AMFR/gp78 招募至內質網細胞質側,也會在 DNA 雙股斷裂後到達損傷位置,或由 SPRTN 招募至停滯複製叉。 砷酸鹽誘發壓力時,VCP 與壓力顆粒共定位;受損且帶有 K48 連結泛素鏈的溶小體亦可募集 VCP。
深綠色圓點:來源記載的蛋白質定位;數量不表示含量。
動物細胞結構示意;器官大小與數量不按比例。點選細胞構造可查看定位註解。
交互作用與訊號網絡
拖曳節點後放開可帶動位置變化;點選夥伴查看證據。位置與連線長度不代表結合強度,圖中未推定夥伴彼此之間的關係。
更多交互作用夥伴 · 已取得 61 個夥伴
- AMFRQ9UKV5 · UniProt INTERACTION · 12 experiments
- ASPSCR1Q9BZE9 · UniProt INTERACTION · 36 experiments
- ATG5A9UGY9 · UniProt INTERACTION · 3 experiments
- ATXN1P54253 · UniProt INTERACTION · 3 experiments
- ATXN3P54252 · UniProt INTERACTION · 4 experiments · 2 筆來源紀錄
- CEP19Q96LK0 · UniProt INTERACTION · 6 experiments
- CHEK2O96017 · UniProt INTERACTION · 2 experiments
- CNOT3O75175 · UniProt INTERACTION · 3 experiments
- CUL4AQ13619 · UniProt INTERACTION · 2 experiments
- DTNBO60941 · UniProt INTERACTION · 4 experiments · 2 筆來源紀錄
- ELAVL4P26378-2 · UniProt INTERACTION · 3 experiments
- EPSTI1Q96J88-3 · UniProt INTERACTION · 3 experiments
- FAF1Q9UNN5 · UniProt INTERACTION · 3 experiments · 2 筆來源紀錄
- FAF2Q96CS3 · UniProt INTERACTION · 16 experiments
- FCHSD2O94868 · UniProt INTERACTION · 2 experiments
- GNAO1P09471 · UniProt INTERACTION · 5 experiments
- GRB2P62993 · UniProt INTERACTION · 5 experiments
- HSPB1P04792 · UniProt INTERACTION · 3 experiments
- HTTP42858 · UniProt INTERACTION · 10 experiments
- LNX1Q8TBB1 · UniProt INTERACTION · 7 experiments
- LZICQ8WZA0 · UniProt INTERACTION · 3 experiments
- METTL17Q9H7H0-2 · UniProt INTERACTION · 3 experiments
- NOD2Q9HC29 · UniProt INTERACTION · 5 experiments
- NPLOC4Q8TAT6 · UniProt INTERACTION · 17 experiments
- NSFL1CQ9UNZ2 · UniProt INTERACTION · 28 experiments
VCP 可形成具有六重徑向對稱的環狀同六聚體,直徑約 12.5 nm。它與 STX5A、NSFL1C 形成的複合體可結合富含磷脂醯乙醇胺的膜並促進高基氏體膜融合;NSFL1C 以同三聚體形式結合在 VCP 六聚體一端。NPLOC4-UFD1 異二聚體結合 VCP 後會抑制高基氏體膜融合,VCIP135 則可透過 VCP 的 ATP 水解促使複合體解離。VCP 另與 p37、SPRTN、AMFR/gp78、DERL 蛋白及多種 UBX domain-containing proteins 形成互作或複合體,參與膜融合、蛋白質逆向轉位與其他細胞功能。
疾病與遺傳關聯
VCP 變異與數種常染色體顯性疾病相關。IBMPFD1 可呈現顯著肌無力、符合 Paget disease 的溶骨性骨病灶,並可能有早發性額顳型失智;臨床特徵的外顯率不完全。FTDALS6 可於成年期出現額顳型失智或肌萎縮性側索硬化症,家族內表現差異大,部分患者同時具有兩者特徵。CMT2Y 則為軸突型周邊神經病變,特徵包括進行性無力與肌肉萎縮,通常先影響腓骨肌,之後涉及手臂遠端肌肉。這些疾病資料描述的是影響 VCP 基因的變異與疾病關聯。
Contextual Functional Evidence Matrix
矩陣以「功能主張」為列,以細胞情境、干預條件、量測結果與證據來源為欄,方便比較同一功能在不同條件下的支持情形。只有含情境與實驗資訊的紀錄會列入矩陣;一般功能註解另列於下方。
功能註解總覽 · 7 筆
| 功能面向 | 功能敘述 | 證據類型 | 可查核來源 |
|---|---|---|---|
| 功能 | VCP 參與內質網與高基氏體膜運輸、高基氏體在有絲分裂期間的分裂及分裂後重組,也協助泛素化錯誤摺疊蛋白由內質網移至細胞質降解。其作用並涵蓋蛋白質品質管制、自噬、壓力顆粒清除、DNA 損傷與複製叉處理、粒線體外膜蛋白清除,以及免疫與受體訊號調節;部分功能明確標示為可能參與。 | 含實驗來源 | 證據與來源Necessary for the fragmentation of Golgi stacks during mitosis and for their reassembly after mitosis. Involved in the formation of the transitional endoplasmic reticulum (tER). The transfer of membranes from the endoplasmic reticulum to the Golgi apparatus occurs via 50-70 nm transition vesicles which derive from part-rough, part-smooth transitional elements of the endoplasmic reticulum (tER). Vesicle budding from the tER is an ATP-dependent process. The ternary complex containing UFD1, VCP and NPLOC4 binds ubiquitinated proteins and is necessary for the export of misfolded proteins from the ER to the cytoplasm, where they are degraded by the proteasome. The NPLOC4-UFD1-VCP complex regulates spindle disassembly at the end of mitosis and is necessary for the formation of a closed nuclear envelope. Regulates E3 ubiquitin-protein ligase activity of RNF19A. Component of the VCP/p97-AMFR/gp78 complex that participates in the final step of the sterol-mediated ubiquitination and endoplasmic reticulum-associated degradation (ERAD) of HMGCR. Mediates the endoplasmic reticulum-associated degradation of CHRNA3 in cortical neurons as part of the STUB1-VCP-UBXN2A complex. Involved in endoplasmic reticulum stress-induced pre-emptive quality control, a mechanism that selectively attenuates the translocation of newly synthesized proteins into the endoplasmic reticulum and reroutes them to the cytosol for proteasomal degradation. Involved in clearance process by mediating G3BP1 extraction from stress granules. Also involved in DNA damage response: recruited to double-strand breaks (DSBs) sites in a RNF8- and RNF168-dependent manner and promotes the recruitment of TP53BP1 at DNA damage sites. Recruited to stalled replication forks by SPRTN: may act by mediating extraction of DNA polymerase eta (POLH) to prevent excessive translesion DNA synthesis and limit the incidence of mutations induced by DNA damage. Together with SPRTN metalloprotease, involved in the repair of covalent DNA-protein cross-links (DPCs) during DNA synthesis. Involved in interstrand cross-link repair in response to replication stress by mediating unloading of the ubiquitinated CMG helicase complex (By similarity). Mediates extraction of PARP1 trapped to chromatin: recognizes and binds ubiquitinated PARP1 and promotes its removal. Required for cytoplasmic retrotranslocation of stressed/damaged mitochondrial outer-membrane proteins and their subsequent proteasomal degradation. Essential for the maturation of ubiquitin-containing autophagosomes and the clearance of ubiquitinated protein by autophagy. Acts as a negative regulator of type I interferon production by interacting with RIGI: interaction takes place when RIGI is ubiquitinated via 'Lys-63'-linked ubiquitin on its CARD domains, leading to recruit RNF125 and promote ubiquitination and degradation of RIGI. May play a role in the ubiquitin-dependent sorting of membrane proteins to lysosomes where they undergo degradation. May more particularly play a role in caveolins sorting in cells. By controlling the steady-state expression of the IGF1R receptor, indirectly regulates the insulin-like growth factor receptor signaling pathway PMID 15456787 ↗ · PMID 16168377 ↗ · PMID 16186510 ↗ · PMID 20104022 ↗ · PMID 21118995 ↗ · PMID 21822278 ↗ · PMID 22020440 ↗ · PMID 22120668 ↗ · PMID 22607976 ↗ · PMID 23042605 ↗ · PMID 23042607 ↗ · PMID 23335559 ↗ · PMID 26265139 ↗ · PMID 26471729 ↗ · PMID 26565908 ↗ · PMID 26692333 ↗ · PMID 27753622 ↗ · PMID 29804830 ↗ · PMID 32152270 ↗ · PMID 34739333 ↗ · PMID 35013556 ↗ · PMID 38762759 ↗ |
| 分子活性 | ATP + H2O = ADP + phosphate + H(+) | 含實驗來源 | |
| 交互作用 | VCP 形成具六重對稱的同六聚體環狀結構,並與多種蛋白質組成複合體。與 STX5A、NSFL1C 組成的複合體可促進高基氏體膜融合;NPLOC4-UFD1 結合則抑制該融合,VCIP135 可透過 VCP ATP 水解促使複合體解離。其他互作涉及蛋白質逆向轉位、ERAD、複製叉募集及自噬等功能。 | 含實驗來源 | 證據與來源Homohexamer. Forms a ring-shaped particle of 12.5 nm diameter, that displays 6-fold radial symmetry. Part of a ternary complex containing STX5A, NSFL1C and VCP. NSFL1C forms a homotrimer that binds to one end of a VCP homohexamer. The complex binds to membranes enriched in phosphatidylethanolamine-containing lipids and promotes Golgi membrane fusion. Binds to a heterodimer of NPLOC4 and UFD1, binding to this heterodimer inhibits Golgi-membrane fusion. Interaction with VCIP135 leads to dissociation of the complex via ATP hydrolysis by VCP. Part of a ternary complex containing NPLOC4, UFD1 and VCP. Interacts with NSFL1C-like protein p37; the complex has membrane fusion activity and is required for Golgi and endoplasmic reticulum biogenesis. Interacts with SELENOS and SYVN1, as well as with DERL1 (via SHP-box motif), DERL2 and DERL3; which probably transfer misfolded proteins from the ER to VCP. Interacts with SVIP and forms a complex with SVIP and DERL1. Component of a complex required to couple retrotranslocation, ubiquitination and deglycosylation composed of NGLY1, SAKS1, AMFR, VCP and RAD23B. Part of a complex composed of STUB1/CHIP, VCP/p97, CHRNA3, and UBXN2A that modulates the ubiquitination and endoplasmic reticulum-associated degradation (ERAD) of CHRNA3. Within the complex UBXN2A acts as a scaffold protein required for the interaction of CHRNA3 with VCP/p97, this interaction also inhibits CHRNA3 ubiquitination by STUB1/CHIP and subsequently ERAD. Interacts with UBXN2A (via UBX domain); the interaction is required for the interaction of CHRNA3 in the STUB1-VCP-UBXN2A complex. Directly interacts with UBXN4 and RNF19A. Interacts with CASR. Interacts with UBE4B and YOD1. Interacts with clathrin. Interacts with RNF103. Interacts with TRIM13 and TRIM21. Component of a VCP/p97-AMFR/gp78 complex that participates in the final step of the endoplasmic reticulum-associated degradation (ERAD) of HMGCR. Interacts directly with AMFR/gp78 (via its VIM). Interacts with RHBDD1 (via C-terminal domain). Interacts with SPRTN; leading to recruitment to stalled replication forks. Interacts with WASHC5. Interacts with UBOX5. Interacts (via N-terminus) with UBXN7, UBXN8, and probably several other UBX domain-containing proteins (via UBX domains); the interactions are mutually exclusive with VIM-dependent interactions such as those with AMFR and SELENOS. Forms a complex with UBQLN1 and UBXN4. Interacts (via the PIM motif) with RNF31 (via the PUB domain). Interacts with RIGI and RNF125; interaction takes place when RIGI is ubiquitinated via 'Lys-63'-linked ubiquitin on its CARD domains, leading to recruit RNF125 and promote ubiquitination and degradation of RIGI. Interacts with BAG6. Interacts with UBXN10. Interacts with UBXN6; the interaction with UBXN6 is direct and competitive with UFD1. Forms a ternary complex with CAV1 and UBXN6. Interacts with PLAA, UBXN6 and YOD1; may form a complex involved in macroautophagy. Interacts with ANKZF1. Interacts with ubiquitin-binding protein FAF1. Interacts with ZFAND2B (via VIM motif); the interaction is direct. Interacts with ZFAND1 (via its ubiquitin-like region); this interaction occurs in an arsenite-dependent manner. Interacts with CCDC47 (By similarity). Interacts with UBAC2 (By similarity). Interacts with LMBR1L. Interacts with ATXN3. Interacts with TEX264; bridging VCP to covalent DNA-protein cross-links (DPCs). Interacts with FBXL4 PMID 15215856 ↗ · PMID 15362974 ↗ · PMID 15456787 ↗ · PMID 16168377 ↗ · PMID 16186509 ↗ · PMID 16186510 ↗ · PMID 16289116 ↗ · PMID 16449189 ↗ · PMID 16513638 ↗ · PMID 16968747 ↗ · PMID 17314412 ↗ · PMID 17872946 ↗ · PMID 18022694 ↗ · PMID 18656546 ↗ · PMID 18675248 ↗ · PMID 19174149 ↗ · PMID 19275885 ↗ · PMID 19818707 ↗ · PMID 19822669 ↗ · PMID 19887378 ↗ · PMID 20512113 ↗ · PMID 20833645 ↗ · PMID 21636303 ↗ · PMID 21822278 ↗ · PMID 21914798 ↗ · PMID 21949850 ↗ · PMID 22120668 ↗ · PMID 22537386 ↗ |
| 細胞定位 | VCP 位於細胞質、細胞溶質、內質網、細胞核與壓力顆粒,也見於肌萎縮性側索硬化症患者運動神經元的神經元玻璃樣包涵體,以及帕金森病患者神經元的 Lewy bodies。它可依特定互作或細胞狀態被募集至內質網表面、DNA 損傷位點、停滯複製叉、受損溶小體及砷酸鹽誘發的壓力顆粒。 | 含實驗來源 | 證據與來源Cytoplasm, cytosol; Endoplasmic reticulum; Nucleus; Cytoplasm, Stress granule; Present in the neuronal hyaline inclusion bodies specifically found in motor neurons from amyotrophic lateral sclerosis patients. Present in the Lewy bodies specifically found in neurons from Parkinson disease patients. Recruited to the cytoplasmic surface of the endoplasmic reticulum via interaction with AMFR/gp78. Following DNA double-strand breaks, recruited to the sites of damage. Recruited to stalled replication forks via interaction with SPRTN. Recruited to damaged lysosomes decorated with K48-linked ubiquitin chains. Colocalizes with TIA1, ZFAND1 and G3BP1 in cytoplasmic stress granules (SGs) in response to arsenite-induced stress treatment PMID 15456787 ↗ · PMID 15215856 ↗ · PMID 23042605 ↗ · PMID 26842564 ↗ · PMID 29804830 ↗ |
| 疾病關聯 | IBMPFD1 為常染色體顯性疾病,可有類似肢帶型肌肉失養症的致殘性肌無力、符合 Paget disease 的溶骨性骨病灶,以及早發性額顳型失智;臨床特徵的外顯率不完全。此疾病與影響 VCP 基因的變異相關。 | 含實驗來源 | 證據與來源Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 1 IBMPFD1 An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance. The disease is caused by variants affecting the gene represented in this entry MIM: 167320 PMID 15034582 ↗ · PMID 15732117 ↗ · PMID 16247064 ↗ · PMID 16321991 ↗ · PMID 17935506 ↗ · PMID 20104022 ↗ · PMID 20335036 ↗ · PMID 20512113 ↗ · PMID 21822278 ↗ · PMID 23349634 ↗ · PMID 25125609 ↗ · PMID 25878907 ↗ · PMID 27209344 ↗ · PMID 27753622 ↗ · PMID 29804830 ↗ · PMID 36980948 ↗ |
| 疾病關聯 | FTDALS6 是常染色體顯性神經退化疾病,可在成年期出現額顳型失智或肌萎縮性側索硬化症,家族內表現差異大,部分患者兼有兩者。額顳型失智涉及額葉及顳葉萎縮、神經元流失、膠質增生與失智,並可能造成社交、行為或語言功能漸進改變;肌萎縮性側索硬化症則涉及腦、腦幹及脊髓運動神經元死亡,可導致致命性癱瘓。疾病與影響 VCP 的變異相關。 | 含實驗來源 | 證據與來源Frontotemporal dementia and/or amyotrophic lateral sclerosis 6 FTDALS6 A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia (FTD) is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis (ALS) is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. FTDALS6 is an autosomal dominant form characterized by onset of ALS or FTD in adulthood. Some patients with the disorder may have features of both diseases. The disease is caused by variants affecting the gene represented in this entry MIM: 613954 PMID 21145000 ↗ · PMID 23349634 ↗ |
| 疾病關聯 | CMT2Y 是常染色體顯性軸突型 Charcot-Marie-Tooth disease,屬周邊神經系統疾病,呈現進行性無力與萎縮,通常先影響腓骨肌,後續涉及手臂遠端肌肉。CMT2 類型以軸突退化為特徵,沒有明顯髓鞘變化,神經傳導速度正常或略降;此疾病與影響 VCP 基因的變異相關。 | 含實驗來源 | 證據與來源Charcot-Marie-Tooth disease, axonal, type 2Y CMT2Y An autosomal dominant, axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. The disease is caused by variants affecting the gene represented in this entry MIM: 616687 PMID 25125609 ↗ · PMID 25878907 ↗ |
核酸與蛋白質序列
AGTCTCAGCGAAGCGTCTGCGACCGTCGTTTGAGTCGTCG40CTGCCGCTGCCGCTGCCACTGCCACTGCCACCTCGCGGAT80CAGGAGCCAGCGTTGTTCGCCCGACGCCTCGCTGCCGGTG120GGAGGAAGCGAGAGGGAAGCCGCTTGCGGGTTTGTCGCCG160CTGCTCGCCCACCGCCTGGAAGAGCCGAGCCCCGGCCCAG200TCGGTCGCTTGCCACCGCTCGTAGCCGTTACCCGCGGGCC240GCCACAGCCGCCGGCCGGGAGAGGCGCGCGCCATGGCTTC280TGGAGCCGATTCAAAAGGTGATGACCTATCAACAGCCATT320CTCAAACAGAAGAACCGTCCCAATCGGTTAATTGTTGATG360AAGCCATCAATGAGGACAACAGTGTGGTGTCCTTGTCCCA400GCCCAAGATGGATGAATTGCAGTTGTTCCGAGGTGACACA440GTGTTGCTGAAAGGAAAGAAGAGACGAGAAGCTGTTTGCA480TCGTCCTTTCTGATGATACTTGTTCTGATGAGAAGATTCG520GATGAATAGAGTTGTTCGGAATAACCTTCGTGTACGCCTA560GGGGATGTCATCAGCATCCAGCCATGCCCTGATGTGAAGT600ACGGCAAACGTATCCATGTGCTGCCCATTGATGACACAGT640GGAAGGCATTACTGGTAATCTCTTCGAGGTATACCTTAAG680CCGTACTTCCTGGAAGCGTATCGACCCATCCGGAAAGGAG720ACATTTTTCTTGTCCGTGGTGGGATGCGTGCTGTGGAGTT760CAAAGTGGTGGAAACAGATCCTAGCCCTTATTGCATTGTT800GCTCCAGACACAGTGATCCACTGCGAAGGGGAGCCTATCA840AACGAGAGGATGAGGAAGAGTCCTTGAATGAAGTAGGGTA880TGATGACATTGGTGGCTGCAGGAAGCAGCTAGCTCAGATA920AAGGAGATGGTGGAACTGCCCCTGAGACATCCTGCCCTCT960cDNA 使用 DNA 字母 T;mRNA 模式改以 U 顯示。轉錄本保留已註解的非編碼區,未另外加入 poly(A) 尾;非編碼 RNA 的參考轉錄本也可能仍需後續加工。數字為所選序列的 1-based 位置。長序列以黃色捲軸瀏覽,可複製或下載完整轉錄本與蛋白質;基因組 DNA 隨捲動取得所需範圍。